Vertex Pharmaceuticals Inc
F:VX1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vertex Pharmaceuticals Inc
F:VX1
|
US |
|
W
|
Westwing Group SE
XMUN:WEW
|
DE |
|
B
|
Baxter International Inc
XBER:BTL
|
US |
|
G
|
Garmin Ltd
DUS:GEY
|
CH |
|
Truist Financial Corp
NYSE:TFC
|
US |
|
MS&AD Insurance Group Holdings Inc
F:59M
|
JP |
|
Polski Koncern Naftowy Orlen SA
OTC:PSKOF
|
PL |
|
K
|
KeyCorp
F:KEY
|
US |
|
F
|
Fast Retailing Co Ltd
F:FR7
|
JP |
|
D
|
Diageo PLC
OTC:DGEAF
|
UK |
|
Aptiv PLC
NYSE:APTV
|
IE |
Wall St Price Targets
VX1 Price Targets Summary
Vertex Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for VX1 is 472.82 EUR with a low forecast of 282.12 EUR and a high forecast of 569.69 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is VX1's stock price target?
Price Target
472.82
EUR
According to Wall Street analysts, the average 1-year price target for VX1 is 472.82 EUR with a low forecast of 282.12 EUR and a high forecast of 569.69 EUR.
What is the Revenue forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
10%
Over the last 14 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 8 years is 10%.
What is the Operating Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
15%
Over the last 14 years, the compound annual growth rate for Operating Income has been 24%. The projected CAGR for the next 8 years is 15%.
What is the Net Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
15%
Over the last 14 years, the compound annual growth rate for Net Income has been 42%. The projected CAGR for the next 8 years is 15%.
